Literature DB >> 27263601

Posterior reversible leukoencephalopathy syndrome in children with hematologic disorders.

Barış Malbora1, Zekai Avcı, Fulden Dönmez, Bülent Alioğlu, Esra Baskın, Füsun Alehan, Namık Özbek.   

Abstract

OBJECTIVE: Posterior reversible leukoencephalopathy syndrome (PRES) is characterized by headache, altered mental status, cortical blindness, and seizures associated with neuroradiological findings. It involves predominantly white matter of the parieto-occipital lobes. Several medications and disorders play a role in the etiology of PRES. In this study, we aimed to show how the prognosis of PRES in hematological diseases of childhood might be according to the etiological factors.
METHODS: Here, we report PRES in six patients, aged 4 to 14 years, with diagnoses of leukemia and aplastic anemia.
RESULTS: Suggested causes in our patients were chemotherapeutics, hypertension, infection and antimicrobial drug administration, tumor lysis syndrome, acute renal failure and hemodialysis, immunosuppressive drug administration, and hypomagnesemia. One of the patients died of sepsis, renal failure and pulmonary hemorrhage and another died of relapse after total recovery from PRES. The other four patients are under follow-up without problems.
CONCLUSION: We suggest that PRES can recover fully with early diagnosis and treatment whereas it can show poor prognosis depending on the etiology.

Entities:  

Year:  2010        PMID: 27263601     DOI: 10.5152/tjh.2010.24

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


  2 in total

1.  Anesthesia and Intensive Care Management in a Pregnant Woman with PRES: A Case Report.

Authors:  Ismail Demirel; Ayse Belin Ozer; Mustafa K Bayar; Salih Burcin Kavak
Journal:  Case Rep Anesthesiol       Date:  2012-07-05

2.  Neurological complication of non Hodgkin lymphoma in childhood: experience from a single center in Turkey.

Authors:  Dogan Kose; Yahya Paksoy; Yavuz Koksal; Ekrem Unal
Journal:  Childs Nerv Syst       Date:  2013-08-30       Impact factor: 1.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.